TR201909747T4 - Aktarım. - Google Patents

Aktarım. Download PDF

Info

Publication number
TR201909747T4
TR201909747T4 TR2019/09747T TR201909747T TR201909747T4 TR 201909747 T4 TR201909747 T4 TR 201909747T4 TR 2019/09747 T TR2019/09747 T TR 2019/09747T TR 201909747 T TR201909747 T TR 201909747T TR 201909747 T4 TR201909747 T4 TR 201909747T4
Authority
TR
Turkey
Prior art keywords
transfer
charge
methods
delivery
binding
Prior art date
Application number
TR2019/09747T
Other languages
English (en)
Inventor
Dixon James
Shakesheff Kevin
Denning Chris
Original Assignee
Univ Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nottingham filed Critical Univ Nottingham
Publication of TR201909747T4 publication Critical patent/TR201909747T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bu buluş, protein aktarımı gibi yük moleküllerinin canlı hücrelere aktarımı, özellikle şunları içeren bir hücreye bir yükün aktarılmasına yönelik bir iletim molekülü ile ilgilidir: bir yük-bağlayıcı molekül ve/veya bir yük; hücrenin yüzeyinde GAG?a bağlanabilen bir glikozaminoglikan (GAG) bağlayıcı eleman; ve bir protein aktarım alanı. Aktarım yöntemleri, aktarım için yükün üretilmesine veya modifiye edilmesine yönelik yöntemler, aktarıma yönelik iletim molekülleri ve aktarımı kullanan veya aktarılmış hücreleri kullanan tedaviye yönelik yöntemler sağlanmaktadır.
TR2019/09747T 2013-12-18 2014-12-18 Aktarım. TR201909747T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1322396.1A GB201322396D0 (en) 2013-12-18 2013-12-18 Transduction

Publications (1)

Publication Number Publication Date
TR201909747T4 true TR201909747T4 (tr) 2019-07-22

Family

ID=50071002

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09747T TR201909747T4 (tr) 2013-12-18 2014-12-18 Aktarım.

Country Status (12)

Country Link
US (2) US10226537B2 (tr)
EP (1) EP3082871B1 (tr)
JP (1) JP6511058B2 (tr)
KR (1) KR20160101083A (tr)
CN (1) CN106102780B (tr)
AU (1) AU2014369443B2 (tr)
CA (1) CA2971291C (tr)
ES (1) ES2733286T3 (tr)
GB (1) GB201322396D0 (tr)
TR (1) TR201909747T4 (tr)
WO (1) WO2015092417A1 (tr)
ZA (1) ZA201604295B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
GB201511158D0 (en) * 2015-06-24 2015-08-05 Univ Nottingham Cell modification and application in therapy
KR101797167B1 (ko) 2016-11-09 2017-11-13 주식회사 바이오셀트란 신규의 프로테인 트랜스덕션 도메인 및 이의 용도
GB201903873D0 (en) * 2019-03-21 2019-05-08 Univ Nottingham Enhanced transfection
WO2020243078A1 (en) * 2019-05-29 2020-12-03 Albert Einstein College Of Medicine Antibody-based method to identify, purify, and manipulate cell types and processes
EP4004017A4 (en) * 2019-07-23 2023-11-22 CSTS Health Care Inc. PLATE-ENABLED DELIVERY OF THERAPEUTIC COMPOUNDS
KR102479847B1 (ko) * 2020-05-13 2022-12-21 주식회사 젠센 새로운 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
WO2022015590A1 (en) * 2020-07-15 2022-01-20 University Of Florida Research Foundation, Incorporated Fibroblast growth factor 7 peptide
KR102556731B1 (ko) * 2020-09-29 2023-07-21 주식회사 젠센 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물
JP7689709B2 (ja) * 2020-10-01 2025-06-09 株式会社Flying Cell 磁性化細胞
JP2024505000A (ja) * 2021-01-27 2024-02-02 シーエスティーエス ヘルス ケア インク． 複数のタンパク質の送達のための血小板アルファ顆粒
US20250228965A1 (en) * 2021-09-15 2025-07-17 Centre National De La Recherche Scientifique Nanoparticles comprising at least one metal salt and at least one peptide
KR102683861B1 (ko) * 2023-04-05 2024-07-11 주식회사 씨지헬스테크 역노화 효과를 나타내는 야마나카 인자의 유전자 전달 효율을 높이는 신규 융합펩타이드 및 이의 용도
WO2025072381A1 (en) * 2023-09-25 2025-04-03 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485250A1 (fr) 1980-06-18 1981-12-24 Commissariat Energie Atomique Cellule photogalvanique, utilisable notamment pour convertir l'energie solaire en energie electrique
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6881825B1 (en) 1999-09-01 2005-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Identication of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and virues
FR2805821B1 (fr) 2000-03-01 2004-01-16 Diatos Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires
EP1174506A1 (en) 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminal Erns peptide and analogues thereof
US20020151004A1 (en) 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
WO2003084481A2 (en) 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
WO2004081188A2 (en) 2003-03-10 2004-09-23 The Regents Of The University Of Michigan Non-toxic membrane-translocating peptides
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
WO2004110359A2 (en) 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Fusion proteins for the treatment of cns
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP1781689A4 (en) * 2004-06-24 2010-11-10 Inst Medical W & E Hall CONJUGATES AND THEIR THERAPEUTIC APPLICATIONS
WO2006036410A2 (en) 2004-08-27 2006-04-06 The Regents Of The University Of California Protection from and treatment of prion protein infection
WO2006029078A2 (en) 2004-09-07 2006-03-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
US20100221235A1 (en) 2006-02-08 2010-09-02 Diatos Compositions and Methods for Treating Lysosomal Storage Diseases
EP1818395A1 (en) 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
JP2009532017A (ja) 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ＰＴＤ／ＣＰＰＳへのｄｓＲＮＡ結合ドメイン融合体によるｓｉＲＮＡの導入可能な送達
KR101394768B1 (ko) 2006-03-30 2014-05-21 드라이스 파마슈티컬스 아이엔씨 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
WO2008006064A2 (en) 2006-07-07 2008-01-10 Georgia Tech Research Corporation Biomimetic polymers and uses thereof
AU2008295509A1 (en) * 2007-08-29 2009-03-12 Tufts University Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits
US8389768B2 (en) 2008-05-19 2013-03-05 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
EP2147683A1 (en) 2008-07-25 2010-01-27 DKFZ Deutsches Krebsforschungszentrum Construct and method for the internalization of cargo molecules into a cell
JP5336275B2 (ja) 2009-06-26 2013-11-06 東京ラヂエーター製造株式会社 尿素水タンク
US20110054236A1 (en) 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2538957B1 (en) 2010-02-26 2019-07-24 Vascular Biosciences, Inc. Car peptide for homing, diagnosis,&targeted therapy for pulmonary and fibrotic disorders
WO2012103256A2 (en) 2011-01-26 2012-08-02 Clontech Laboratories, Inc. Enhanced protein transduction
US20140073557A1 (en) 2011-03-16 2014-03-13 Protaffin Biotechnologie Ag Fgfri-based antagonists with improved glycosaminoglycan affinity and methods of using same
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
EP2864360B1 (en) * 2012-06-25 2017-09-06 The Brigham and Women's Hospital, Inc. Targeted therapeutics
KR101456026B1 (ko) 2012-09-18 2014-11-04 서울대학교산학협력단 종양선택적 투과기능성을 가지는 펩타이드 및 그 용도
US20160031985A1 (en) 2013-03-15 2016-02-04 Katherine S. Bowdish Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
KR101529634B1 (ko) 2013-08-28 2015-06-30 서울대학교산학협력단 역분화 유도를 위한 세포투과성 융합 단백질 및 그 용도
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction

Also Published As

Publication number Publication date
CN106102780A (zh) 2016-11-09
JP2017501710A (ja) 2017-01-19
ES2733286T3 (es) 2019-11-28
US10226537B2 (en) 2019-03-12
ZA201604295B (en) 2022-04-28
AU2014369443A1 (en) 2016-07-14
US20170080101A1 (en) 2017-03-23
CN106102780B (zh) 2020-11-10
EP3082871A1 (en) 2016-10-26
KR20160101083A (ko) 2016-08-24
US11672870B2 (en) 2023-06-13
JP6511058B2 (ja) 2019-05-08
AU2014369443B2 (en) 2019-08-01
WO2015092417A1 (en) 2015-06-25
GB201322396D0 (en) 2014-02-05
EP3082871B1 (en) 2019-05-01
CA2971291A1 (en) 2015-06-25
CA2971291C (en) 2022-08-30
US20190216941A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
TR201909747T4 (tr) Aktarım.
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
MX389160B (es) Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas.
CY1119518T1 (el) Τροποποιημενα αντιγονα φυματιωσης
PL3313991T3 (pl) Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek
EA201891212A1 (ru) Адресная дезорганизация клеточного рецептора гкгс
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX2016007063A (es) Peptidos terapeuticos.
MX374682B (es) Moléculas de unión a 4-1bb.
PH12015502039A1 (en) Anti-lag-3 binding proteins
EA201000146A1 (ru) Связующее майларда на основе гидроксимонокарбоновой кислоты
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
UY33647A (es) ?agentes de unión a cd33?.
CL2015000829A1 (es) Inhibidores de histona desmetilasas
CY1119093T1 (el) Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο
UY34254A (es) Proteínas y péptidos modificados.
MX374906B (es) Nuevos inmunoconjugados
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
EA201591454A1 (ru) Связывающие внеклеточный матрикс синтетические пептидогликаны
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
BR112012018021A2 (pt) antídotos anticoagulantes.
MX2016002166A (es) Anticuerpos.
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna